Objetivo
The infectious diseases burden imposed by the parasites of Trypanosomatidae family represents a huge problem on people’s lives in countries where these diseases are endemic. Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. New drugs are urgently needed now and in the foreseeable future. The New Medicine for Trypanosomatid Infections (NMTrypI) consortium uses a highly interdisciplinary approach to optimize pteridine, benzothiazole and miltefosine derivatives, as well as natural products against Trypanosomatids. The lead compounds target mechanisms that are associated with protozoa virulence and pathogenicity. The major objectives of this 3-year project are: i) development of drug leads which may be used in combination with a known or an investigational drugs, by using a common drug discovery platform established by experts in their respective fields, ii) development of pharmacodynamic biomarkers enabling the proteomic profiling of compound efficacy and early identification of drug resistance. NMTrypI addresses sleeping sickness, leishmaniasis, and Chagas disease. The partners are SMEs (5) and academics (8) in Europe and in disease-endemic countries (Italy, Greece, Portugal, Sudan, and Brazil). The new platform enables high throughput screening of compound libraries, lead development, testing in relevant animal models, as well as toxicology and safety testing. NMTrypI will translate drug leads into drug candidacy through 6 scientific work packages (WPs1-6) supported by two transversal WPs dedicated to project dissemination and management. The major strength of the consortium lies in the complementary partners’expertise and the integrated platform that will provide:
- at least 1-2 innovative, less toxic and safer drug candidates for Trypanosomatid infections compared to existing ones,
- early phase biomarkers for efficacy prediction (overall improved efficacy and safety)
Ámbito científico
- medical and health sciencesclinical medicinepsychiatrysleep disorders
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistance
- medical and health sciencesbasic medicinetoxicology
Convocatoria de propuestas
FP7-HEALTH-2013-INNOVATION-1
Consulte otros proyectos de esta convocatoria
Régimen de financiación
CP-FP - Small or medium-scale focused research projectCoordinador
41121 Modena
Italia
Ver en el mapa
Participantes (13)
22525 Hamburg
Ver en el mapa
20359 Hamburg
Ver en el mapa
4200 135 Porto
Ver en el mapa
53100 Siena
Ver en el mapa
69118 Heidelberg
Ver en el mapa
41126 Modena
Ver en el mapa
11111 Khartoum
Ver en el mapa
SL6 6QH Maidenhead
Ver en el mapa
11635 Athina
Ver en el mapa
28040 Madrid
Ver en el mapa
La participación finalizó
1000 Bruxelles
Ver en el mapa
13083 100 Campinas
Ver en el mapa
80686 Munchen
Ver en el mapa